

**Date: December 12, 2024**

**BSE Limited**

P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Script Code: 543904**

**Symbol: MANKIND**

Dear Sir/ Madam,

**Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations)**

---

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has received an Order on 12 December 2024 from Office of Superintendent, CGST, Dehradun – issued by Superintendent (“Department”) under Section 74 of the CGST Act, 2017. Based on the assessment of facts and prevailing law, the Company is of the view that the aforesaid order is arbitrary and unjustified. The Company will file necessary appeal with the appellate authority in this regard. There is no material impact on financials, operations or other activities of the Company.

The detailed disclosure as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 for aforesaid is enclosed as annexure I.

This is for your information and records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Ashish Mittal**

**Company Secretary and Compliance Officer**

## Annexure – I

Disclosure as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Sr. No.	Details of event that needs to be provided	Details
1	Name of the authority	Superintendent – CGST, Range-V, Dehradun (“Department”)
2	Nature and details of the action(s) taken, initiated or order(s) passed;	Order-in-Original dated 22 November 2024 passed u/s 74 of Central Goods and Services Tax Act, 2017 covering financial year 2017-18 to FY 2018-19 levying penalty of INR 243,148/-
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority;	Order dated November 22, 2024 but passed and received on 12 December, 2024
4	Details of the violation(s)/contravention(s) committed or alleged to be committed;	The GST Authority has passed the Order, pursuant to GST audit on the contention that there is a mismatch in the figures reported in GSTR -1 vis-à-vis GSTR-9 and the books.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible;	<p>Based on the assessment of facts and prevailing law, the Company is of the view that the demand including penalty levied is arbitrary and unjustified.</p> <p>The Company is exploring various options available to take appropriate steps, including filing of an appeal if required.</p> <p>There is no material impact on the company's financials, operations, or other activities.</p>

**MANKIND PHARMA LIMITED**

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600  
CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com